Summary We examined the reactivity of four p53-specific monoclonal antibodies -PAb 1801, p53-BP-12, D07 and CMI -on sections of formalin-fixed tissue collected from 245 breast carcinomas. Immunodetection of p53 varied between 37.6% and 46.6%. The greatest variation was observed among lobular carcinomas and low-grade tumours in which immunodetection varied between 8.3% and 27.3%. In contrast, immunodetection of p53 in invasive ductal carcinomas was subject to a lower degree of variability with between 40.6% and 49.7% of these tumours proving to be positive. In general, we found antibodies PAb 1801 and D07 to be the most effective in immunolocalising p53. Immunodetection of p53 with each of the four antibodies was found to correlate strongly with tumour grade. In survival analysis, the results gained using antibody PAb 1801 proved to be of greatest statistical significance and to provide the strongest index of prognosis. A significant relationship was observed between immunodetection of p53 with each of the four antibodies and poor responsiveness to endocrine therapy. In addition, relationships were also observed between p53 immunostaining and tumour oestrogen receptor (ER) (Iwaya et al., 1991; Sawan et al., 1992; Barnes et al., 1993; Yamashita et al., 1993).
Prediction of likely outcome in breast cancer has acquired greater importance following the demonstration by metaanalysis that chemotherapy provides enhanced 10 year survival rates (Early Breast Cancer Trials Collaborative Group, 1992) . Accurate prediction of outcome would allow rational allocation of patients to appropriate treatment regimens. Lymph node status is accepted as a primary prognostic factor but it is recognised that greater predictive power would be desirable, and numerous potential prognostic factors have been examined, for example tumour grade, hormone receptor status and c-erb-B2 protein expression. (Barnes et al., 1989; Neville et al., 1990; Galea et al., 1992) . Cattoretti et al. (1988) were the first to demonstrate that p53 gene expression might serve as a prognostic indicator in breast cancer. This has subsequently been confirmed by other workers who have shown that p53 protein overexpression determined by immunohistochemistry gives significant supplementary information regarding likely outcome (Iwaya et al., 1991; Sawan et al., 1992; Barnes et al., 1993; Yamashita et al., 1993) .
The p53 gene is located on the short arm of chromosome 17 and it encodes a 53 kDa nuclear phosphoprotein involved in the control of cell proliferation (Baker et al., 1989) . The exact function of the p53 protein is not fully understood but it may play a role in DNA replication and regulation of transcription (Levine et al., 1991) . Recent studies have shown that p53 in its 'wild' form may act as a tumour-suppressor gene (Lane and Benchimol, 1990 ). The precise mechanism of p53 tumour suppression is not known. Recent evidence suggests that p53 indirectly inhibits cell proliferation by regulating the transcription of other unidentified genes (Kern et al., 1992) . The p53 gene has been found mutated and/or deleted in a wide range of tumours (Mulligan et al., 1990; Levine et at., 1991) . Functional inactivation of the p53 gene by mutation or allelic loss appears to be one of the commonest genetic abnormalities in human cancer (Lane, 1992) . Structural abnormalities of the p53 gene have been detected in sarcomas, leukaemias, colonic, lung, oesophageal apd liver carcinomas (Vogelstein and Kinzler, 1992) . Mutation leads to altered protein conformation and increased half-life of the p53 gene product, resulting in detectability by immunohistochemistry. Recent immunohistochemical studies have shown that the detection rate of mutated p53 protein in breast cancer ranges between 13% and 53.5% (Cattoretti et al., 1988; Sawan et al., 1992; Martinazzi et al., 1993; Yamashita et al., 1993) .
The aim of the present study was to assess the expression of the p53 gene in a large series of routinely processed human breast carcinomas and its relation to tumour variables, prognostic factors and patient outcome. In doing so we compared the effectiveness of four different antibodies commonly used in immunolocalisation studies of p53.
Materials and methods

Tissues
Our study included 245 resected breast carcinomas from 245 female patients (mean age: 57.02 years with a standard deviation of 13.87, range: 24-98 years) attending the Royal Victoria Infirmary, Newcastle upon Tyne, UK between 1983 and 1990. Tumour tissues were received fresh in the Department of Pathology, were dissected and block-sized pieces were fixed overnight in neutral buffered formalin. Following primary fixation the blocks were further trimmed and postfixed in formal sublimate (saturated aqueous mercuric chloride and 37% formaldehyde, 9: 1) for approximately 3 h. Blocks were then routinely paraffin embedded. The histological classification of the tumours was based on the WHO criteria and the grading was according to the criteria of Bloom and Richardson modified by Elston (Elston and Ellis, 1991 The patient group has been the subject of other prognostic studies. Data concerning oestrogen receptor (ER), progesterone receptor (PgR) and epidermal growth factor receptor (EGFR) status determined by frozen section immunohistochemistry (Elston and Ellis. 1991; Piggott et al., 1991; Sawan et al., 1992) , expression of c-erbB-2 and c-jun oncoproteins and expression of Rb protein determined by paraffin section immunochemistry were available (Corbett et al., 1990; Anderson et al., 1994; Tiniakos et al., 1994) . In addition, a small subgroup of patients (n = 17) has been previously assessed regarding response to endocrine therapy on relapse, and these data were also available for comparative studies. The minimum criterion for response to hormonal therapy on relapse was disease that did not progress for at least 6 months .
Immunohistochemical method and antibodies The streptavidin-biotin complex (sABC) (Dakopatts, Denmark) immunoperoxidase techique was used on 5-gm-thick paraffin sections. 
Statistical analysis
The chi-squared test, together when appropriate with Yeat's correction, was used for the correlations between the different tumour and patient variables. Log-rank tests were used for survivial analyses. All analyses were carried out using Solo Statistical Software (BMDP Statistical Software, USA). Lymph node status was the most powerful predictive factor for both time to relapse and time to death (P = 0.021 and P = 0.0001 respectively). Using the monoclonal antibody PAb 1801, p53 expression was associated with poorer overall survival when all patients were considered (P = 0.017); in subgroups stratified by node status this observation was sustained only in the node-negative group (P = 0.037) ( Figure  2 ). When relapse-free survival was assessed, immunostaining for p53 using PAb 1801 was not associated with poorer prognosis. Immunostaining for p53 protein did not relate significantly to survival or relapse-free survival, using D07, p53-BP-12 and CM1 antibodies. When groups of patients were defined according to positivity for any antibody, compared with negativity for all antibodies, no survival differences for either of these groups was observed, either taking the data as a whole, or by stratification according to node status.
Using each one of the four antibodies, p53 expression correlated positively with higher tumour grade (P = 0.0014, PAb 1801; P = 0.0004, p53-BP-12; P = 0.0012, D07; P = 0.0249, CM 1) (Figure 3 ). Staining using D07 correlated significantly with negative ER status, as determined with the anti-ER monoclonal antibody ERLH1 (Henry et al., 1993);  in general p53-negative breast carcinomas were more fre- CM 1, % = 4.129) ( Figure 5 ). Thus in each instance this relationship proved statistically significant (PAb 1801 P=0.00064; p53-BP-12 P=0.00069; D07 P=0.00516; CM1 P = 0.00064). Although the number of patients within this group was small, incorporating only 17 patients, it was notable that no p53-positive individual showed a response to endocrine therapy. Using the antibody PAb 1801, our results also suggested a relationship between tumour p53 immunostaining and c-jun (P = 0.0307). Our data indicated that although most tumours appeared to express c-jun, approximately two-thirds of this group were found to be p53 negative, while in contrast three-quarters of the c-jun-negative tumours were found to be p53 positive. As a result, p53-negative tumours were found to be approximately five times more likely to be c-jun positive than p53-positive tumours. Finally, no significant relationship was observed between p53 expression and cerbB-2 oncoprotein, retinoblastoma gene protein, EGFR and progesterone receptor expression.
Discussion
Abnormalities in the p53 gene, either in the form of gene loss or in the form of mutations, are the most common genetic abnormality in primary breast carcinoma . The human p53 gene has been mapped on the short arm of chromosome 17, where other genes with prognostic significance in breast cancer, such as c-erbB-2 and the antimetastatic gene nm23, are also located (Sawan et al., 1994) .
Our study compared one polyclonal and three monoclonal antibodies, which have often been used previously, in isolation, in immunohistochemical studies that have sought to define tumour p53 status. We sought to gain a consensus by applying each of these antibodies in parallel to study p53 expression/stabilisation within a large series of breast carcinomas. The three monoclonal antibodies employed in this comparison, namely D07, PAb 1801 and p53-BP-12, are each known to react with the amino-terminal portion of the p53 molecule, which is distal to the central region, which is most frequently affected by point mutations. Thus, we would expect a high degree of structual conservation within the N-terminal region reactive with these antibodies. Although each of the monoclonal antibodies recognises the immunodominant N-terminal portion of the p53 molecule, the precise location of their complementary epitopes varies between two sites. Antibody PAb 1801 is known to recognise an epitope mapping between amino acid residues 32 and 79 (Banks et al., 1986) while antibodies BP-53-12 and D07 react with the same epitope within the region defined by amino acids 20 -25 (Stephen et al., 1995) . In addition, this Nterminal sequence of amino acids is also known to overlap with a seven amino acid sequence (18) (19) (20) (21) (22) (23) , that constitutes the binding site for the p53 modulatory protein MDM2 (Picksley et al., 1994) .
In the present study, the detection rate of p53 protein in breast carcinoma varied from 37.6% to 46.6%, depending on the anti-p53 antibody used. These results are in keeping with the findings of previous similar studies (Cattoretti et Previous studies have shown that the presence of detectable p53 protein in breast cancer is significantly correlated with increased levels of c-erbB-2 oncoprotein (Iwaya et al., 1991; Barbareschi et al., 1992; Poller et al., 1992; Spandidos et al., 1992; Martinazzi et al., 1993) , and EGFR Poller et al., 1992) , but similar correlations were not observed in our material. Correlation between Rb and p53 structural abnormalities has been reported in breast carcinoma and in several other malignant tumours (Hall and Lane, 1994) . In our study and in others, no correlation was found between the expression of Rb and p53 genes at the cellular level. Trudel et al., 1992) . However, within this same series of tumours a significant relationship was observed between expression of Rb and cyclin Dl . An interesting finding reported in the current study for the first time, was the significant correlation of the immunolocalisation of p53 protein with the apparent absence of c-jun oncoprotein in the breast cancer cells.
Of great interest is our observation that p53 overexpression (as determined by any of the four antibodies), is associated with patients' failure to respond to endocrine therapy. While it is true that p53-positive tumours tend to be negative for ER and to be of high grade, this observation clearly requires further investigation since our Immunodetection of p53 protein has been recently reported in normal cells following genotoxic injury, which leads to stabilisation of the wild-type p53 (MacKay et al., 1988) . The evaluation of the results of the immunohistochemical detection of p53 protein, should be carried out with great care since the observed tumour immunophenotypes do not always reflect the underlying biochemical and biological cellular changes. It will clearly be of importance to compare the prognostic significance of mutation per se to overexpression determined by immunostaining and this is now proceeding in our laboratory. In addition, since we have demonstrated the differing prognostic significance of p53 determined by various antibodies, it will now be important to investigate the significance of the relationship between such staining differences (perhaps reflecting different molecular forms), specific mutations and survival.
It is clear that in the study of p53 alterations in human tumours, it is no longer sufficient to designate cases as 'p53 positive'. Rather, the molecular change must be carefully defined by the antibody used for immunohistochemistry or by DNA analysis for mutation, and ideally both. In addition, assessment of expression of DNA binding proteins such as MDM2 may be important.
This study demonstrates that the relationship of p53 over expression to clinical outcome is complex, and that more comprehensive analysis is required to translate the results into reliable clinical guidelines.
